The litigation, brought on behalf of investors by Bleichmar Fonti & Auld LLP, centers on the company’s handpiece sales for its robotic surgery systems. While Procept previously maintained that handpiece shipments aligned consistently with procedure volume, the complaint alleges these figures were bolstered by an extensive discount program. This strategy reportedly led to a cumulative excess field inventory of more than 10,000 units by early 2026.

Investors suffered significant losses following disclosures regarding these inventory imbalances. The most severe impact occurred after the company’s February 2026 announcement, which revealed a 30% contraction in U.S. handpiece unit sales, triggering an 18% drop in stock price over two trading days. Previous quarterly reports in August and November 2025 similarly prompted double-digit declines as the company adjusted its sales guidance and admitted to customer overstocking. Shareholders seeking to serve as lead plaintiff in the case, captioned Operating Engineers Construction Industry and Miscellaneous Pension Fund v. PROCEPT BioRobotics Corporation, must file by September 22, 2026.